Discovery of cyclin-dependent kinase inhibitor, CR229, using structure-based drug screening

Journal of Microbiology and Biotechnology

Volumn 17, Issue 10, 2007, Pages 1712-1716

  Kim, Min Kyoung ^a   Min, Jaeki ^b   Choi, Bu Young ^b   Lim, Haeyoung ^a   Cho, Youl Hee ^a   Lee, Chul Hoon ^a  

^a Hanyang University   (South Korea)

^b C and C Research Laboratories   (South Korea)

Author keywords

CDK inhibitor; CR229; Structure based drug screening

Indexed keywords

6 BROMO 2,3,4,9 TETRAHYDRO CARBOLIN 1 ONE; ADENOSINE TRIPHOSPHATE; CASEIN KINASE II; CR 229; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; GLUTAMINE; HYMENIALDISINE; INDIRUBIN; LEUCINE; OXINDOLE; PROTEIN KINASE C; QUINAZOLINE; ROSCOVITINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME BINDING; HELA CELL; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; PHARMACOPHORE; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; CARBOLINES; CASEIN KINASE II; CDC2 PROTEIN KINASE; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIN-DEPENDENT KINASES; DRUG EVALUATION, PRECLINICAL; HELA CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36049007464     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Choi, Y. H., W. H. Lee, K. Y Park, and L. Zhang. 2000. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Cancer Sci. 91: 164-173.
2. Davis, S. T., B. G. Benson, H. N. Bramson, D. E. Chapman, S. H. Dickerson, K. M. Dold, D. J. Eberwein, M. Edelstein, S. V. Frye, R. T. Gampe, R. J. Griffien, P. A. Harris, A. M. Hassell, W. D. Holmes, R. N. Hunter, V. B. Knick, K. Lackey, B. Lovejoy, M. J. Luzzio, D. Murray, P. Parker, W. J. Rocgue, L. Shewchuk-Chapman, J. M. Veal, D. H. Walker, and L. F. Kuyper. 2001. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 291: 134-137.
3. Desjarlais, R. L. 1997. Generation and use of three-dimensional databases for drug discovery, pp. 73-104. In P. S. Charifson (ed.), Practical Application of Computer-aided Drug Design. Marcel Dekker, New York, U.S.A.
4. Doerig, C., L. Meijer, and J. C. Mottram. 2002. Protein kinases as drug targets in parasitic protozoa. Trends Parasitol. 18: 366-371.
5. Gray, N., L. Detivaud, C. Doerig, and L. Meijer. 1999. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6: 859-875.
6. Honma, T., K. Hayashi, T. Aoyama, N. Hashimoto, T. Machida, K. Fukasawa, T. Iwama, C. Ikeura, M. Ikuta, I. Suzuki-Takahashi, Y. Iwasawa, T. Hayama, S. Nishimura, and H. Morishima. 2001. Structure-based generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library design. J. Med. Chem. 44: 4615-4627.
7. Kakizaki, I., K. Ookawa, T. Ishikawa, M. Hayakari, T. Aoyagi, and S. Tsuchida. 2000. Induction of apoptosis and cell cycle arrest in mouse colon 26 cells by benastatin A. Cancer Sci. 91: 1161-1168.
8. Kawanishi, N., T. Sugimoto, J. Shibata, K. Nakamura, K. Masutani, M. Ikuta, and H. Hirai. 2006. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg. Med. Chem. Lett. 16: 5122-5126.
9. Kim, H. J., J. H. Kim, C. H. Lee, and H. J. Kwon. 2006. Gentisyl alcohol, an antioxidant from microbial metabolite, induces angiogenesis in vitro. J. Microbiol. Biotechnol. 16: 475-479.
10. Kim, H. J. and H. J. Kwon. 2007. Synthesis and biological activity of fungal metabolite, 4-hydroxy-3-(3'-metbyl-2'-butenyl)-benzoic acid. J. Microbiol. Biotechnol. 17: 543-545.
11. Kim, M. K., Y.-H. Cho, J. M. Kim, M. W. Chun, S. K. Lee, Y. Lim, and C.-H. Lee. 2005. Induction of apoptosis in human leukemia cells by MCS-C2 via caspase-dependent Bid cleavage and cytochrome c release. Cancer Lett. 223: 239-247.
12. Knockaert, M., P. Greengard, and L. Meijer. 2002. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23: 417-425.
13. Lim, H., M. K. Kim, Y.-H. Cho, J. M. Kim, Y. Lim, and C.-H. Lee. 2004. Inhibition of cell cycle progression and induction of apoptosis in HeLa cells by HY558-1, a novel CDK inhibitor isolated from Penicillium minioluteum F558. J. Microbiol. Biotechnol. 14: 978-984.
14. Lim, H., M. K. Kim, Y. Lim, Y.-H. Cho, and C.-H. Lee. 2006. Inhibition of cell-cycle progression in HeLa cells by HY52, a novel cyclin-dependent kinase inhibitor isolated from Bauhinia forficata. Cancer Lett. 233: 89-97.
15. Lim, H., Y. Lim, Y.-H. Cho, and C.-H. Lee. 2006. Induction of apoptosis in the HepG2 cells by HY53, a novel natural compound isolated from Bauhinia forficata. J. Microbiol. Biotechnol. 16: 1262-1268.
16. Lim, H., H. L. Oh, and C.-H. Lee. 2006. Effect of Aralia continentalis root extract on cell proliferation and apoptosis in human promyelocytic leukemia HL-60 cells. J. Microbiol. Biotechnol. 16: 1399-1404.
17. Obaya, A. J. and J. M. Sedivy. 2002. Regulation of cyclin-CDK activity in mammalian cells. Cell. Mol. Life Sci. 59: 126-142.
18. Osuga, H., S. Osuga, F. Wang, R. Fetni, M. J. Hogan, R. S. Stack, A. M. Hakim, J. E. Ikeda, and D. S. Park. 2000. Cyclin-dependent kinases as a therapeutic target for stroke. Proc. Natl. Acad. Sci. USA 97: 10254-10259.
19. WAFI/CIPI pathway. Cancer Sci. 97: 430-436.
20. Schang, L. M., A. Rosenberg, and P. A. Schaffer. 2000. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes siniplex virus DNA synthesis in the presence of viral early proteins. J. Virol. 74: 2107-2120.
21. Shapiro, G. I. 2006. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24: 1770-1783.
22. Sherr, C. J. 1996. Cancer cell cycle. Science 274: 1672-1677.
23. Sherr, C. J. 1993. Mammalian G1 cyclins. Cell 73: 1059-1065.
24. Sherr, C. J. and J. A Roberts. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13: 1501-1512.
25. Takizawa, C. G. and D. O. Morgan. 2000. Control of mitosis by changes in the subcellular location of cyclin-B1-CDK1 and Cdc25C. Curr. Opin. Cell Biol. 12: 658-665.
26. Vakser, I. A. and C. Aflalo. 1994. Hydrophobic docking: A proposed enhancement to molecular recognition techniques. Proteins 20: 320-329.
27. Vulpetti, A., E. Casale, F. Roletto, R. Amici, M. Villa, and P. Pevarello. 2006. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors. J. Mol. Graph. 24: 341-348.
28. Wang, D., C. de la Fuente, L. Deng, L. Wang, I. Zilberman, C. Eadie, M. Healey, D. Stein, T. Denny, L. E. Harrison, L. Meijer, and F. Kashanchi. 2001. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75: 7266-7279.